Co-Diagnostics anticipates India TB test commercialization by Q3 '26 while exploring CoSara SPAC options
Source: SeekingAlpha
2026-04-01 02:43:39 ET
More on Co-Diagnostics
- Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Co-Diagnostics
- Historical earnings data for Co-Diagnostics
- Financial information for Co-Diagnostics
Read the full article on Seeking Alpha
For further details see:
Co-Diagnostics anticipates India TB test commercialization by Q3 '26 while exploring CoSara SPAC options
Co-Diagnostics Inc.
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
CODX Latest News
May 19, 2026 09:00:00 am
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak AlertCODX Stock Data
$4,902,373
1,981,899
N/A
2
2252057%
Medical Equipment & Supplies
Healthcare
US
Salt Lake City
